(Reuters) - An experimental treatment for attention deficit hyperactivity disorder from Targacept Inc did not meet the main goal of a mid-stage trial, prompting the company to drop development of the drug and cut jobs. Targacept shares fell as much as 12.4 percent on Monday after the results showed that patients in the placebo group had improved more than those taking the experimental drug, TC-5619. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment